BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29925392)

  • 1. Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia.
    Wu S; Du Y; Beckford J; Alachkar H
    J Transl Med; 2018 Jun; 16(1):170. PubMed ID: 29925392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circular RNA of vimentin expression as a valuable predictor for acute myeloid leukemia development and prognosis.
    Yi YY; Yi J; Zhu X; Zhang J; Zhou J; Tang X; Lin J; Wang P; Deng ZQ
    J Cell Physiol; 2019 Apr; 234(4):3711-3719. PubMed ID: 30152863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of pseudogene Vimentin 2p is associated with poor outcome in de novo acute myeloid leukemia.
    Zhai LL; Zhou J; Zhang J; Tang X; Zhou LY; Yin JY; Vanessa MD; Peng W; Lin J; Deng ZQ
    Cancer Biomark; 2017; 18(3):305-312. PubMed ID: 28106537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
    Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
    Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
    Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
    Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA VIM-AS1 promotes colorectal cancer progression and metastasis by inducing EMT.
    Rezanejad Bardaji H; Asadi MH; Yaghoobi MM
    Eur J Cell Biol; 2018 May; 97(4):279-288. PubMed ID: 29656793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Wang WD
    Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical significance of vimentin-expressing gastric cancer cells in bone marrow.
    Iwatsuki M; Mimori K; Fukagawa T; Ishii H; Yokobori T; Sasako M; Baba H; Mori M
    Ann Surg Oncol; 2010 Sep; 17(9):2526-33. PubMed ID: 20358301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of epithelial-mesenchymal transition and cancer stem cell markers in colorectal adenocarcinoma: Clinicopathological significance.
    Choi JE; Bae JS; Kang MJ; Chung MJ; Jang KY; Park HS; Moon WS
    Oncol Rep; 2017 Sep; 38(3):1695-1705. PubMed ID: 28677737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vimentin expression is associated with decreased survival in gastric cancer.
    Otsuki S; Inokuchi M; Enjoji M; Ishikawa T; Takagi Y; Kato K; Yamada H; Kojima K; Sugihara K
    Oncol Rep; 2011 May; 25(5):1235-42. PubMed ID: 21327330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
    Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
    BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia.
    Cheng H; Huang C; Xu X; Hu X; Gong S; Tang G; Song X; Zhang W; Wang J; Chen L; Yang J
    J Transl Med; 2017 Aug; 15(1):179. PubMed ID: 28851457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Ang Q; Wang GJ; Zhu J; Wang WD
    Oncotarget; 2016 Jan; 7(3):2585-95. PubMed ID: 26506237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulated vimentin and upregulated E-cadherin in T1 stage non-small-cell lung cancer: does it suggest a mesenchymal-epithelial transition?
    Luo T; Wang L; Wu P; Gong W; Chen W; Zhao H; Zheng Z
    Neoplasma; 2017; 64(5):693-699. PubMed ID: 28592120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients.
    Tiribelli M; Raspadori D; Geromin A; Cavallin M; Sirianni S; Simeone E; Bocchia M; Fanin R; Damiani D
    Leuk Res; 2017 Jul; 58():31-38. PubMed ID: 28407515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.
    Li Y; Lin J; Yang J; Qian J; Qian W; Yao DM; Deng ZQ; Liu Q; Chen XX; Xie D; An C; Tang CY
    Leuk Res; 2013 Dec; 37(12):1642-7. PubMed ID: 24138945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSPG2 overexpression independently predicts poor survival in patients with acute myeloid leukemia.
    Zhou X; Liang S; Zhan Q; Yang L; Chi J; Wang L
    Cell Death Dis; 2020 Jun; 11(6):492. PubMed ID: 32606327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
    Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
    Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.